Treatment with Trabodenoson significantly increases MMP-2 activity and MMP-14 abundance, while decreasing expression of fibronectin and collagen IV[2].

Trabodenoson (6.0%) demonstrates an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation)[2].
In induced eyes, topical trabodenoson significantly upregulates nestin expression in the ONH compared with vehicle-treated non-induced eyes[1].
Trabodenoson-treated eyes show significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. Additionally, RGC counts are higher in Trabodenoson-treated eyes compared to vehicle, accounting for 74% versus 47% of the contralateral eye[1].